文献速递细菌感染、耐药与抗菌药物

观察性研究与随机对照试验在抗生素治疗疗程研究中的比较:一项叙述性综述

Observational versus randomized controlled trials to inform antibiotic treatment durations: a narrative review.
PubMed 文献 · Clin Microbiol Infect · 2022-09-13

该叙述性综述以无并发症革兰阴性菌血症为例,比较观察性研究与随机对照试验在评估抗生素疗程时的优势与局限。检索MEDLINE至2022年6月9日,纳入10项研究(7项观察性研究、3项RCT),采用贝叶斯随机效应荟萃分析。30天死亡率方面,长疗程更优的后验概率在RCT中为42%(OR 0.94;95% CrI 0.51-1.68),在观察性研究中为91%(OR 1.25;95% CrI 0.88-1.73)。

要点

  • RCT中长疗程更优的后验概率为42%(OR 0.94;95% CrI 0.51-1.68)。
  • 观察性研究中长疗程更优的后验概率为91%(OR 1.25;95% CrI 0.88-1.73)。
  • 无一项观察性研究完全处理了所有潜在偏倚来源。

核心结论

  • 基于本综述发现,作者讨论了抗生素疗程试验的未来方向,包括限制观察性数据偏倚来源的方法及新型试验设计。

研究设计与样本

  • 叙述性综述,检索MEDLINE自建库至2022年6月9日比较革兰阴性菌血症疗程的文章。
  • 纳入报告28-30天全因死亡率和/或复发的研究,共10项(7项观察性研究、3项RCT)。
  • 采用贝叶斯随机效应荟萃分析合并短疗程与长疗程比较数据,按研究设计分层。

主要发现

  • 共识别1671条唯一记录,最终纳入10项研究(7项观察性研究、3项RCT)。
  • 30天死亡率方面,长疗程更优(即OR>1.0)的贝叶斯后验概率在RCT中为42%(OR 0.94;95% CrI 0.51-1.68),在观察性研究中为91%(OR 1.25;95% CrI 0.88-1.73)。
  • 无一项观察性研究完全处理了所有潜在偏倚来源。

关键数值与推荐

  • 30天死亡率长疗程更优的后验概率:RCT为42%(OR 0.94;95% CrI 0.51-1.68),观察性研究为91%(OR 1.25;95% CrI 0.88-1.73)。
  • 纳入标准为报告28-30天全因死亡率和/或复发的研究。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 无一项观察性研究完全处理了所有潜在偏倚来源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies comparing shorter and longer antibiotic treatment durations are increasingly common. Randomized controlled trials (RCTs) are an ideal methodological approach to study antibiotic treatment durations; however, these trials can be logistically and financially challenging to conduct. OBJECTIVES: In this narrative review, we sought to compare the strengths and limitations of observational study data with those of RCT data in evaluating antibiotic treatment durations. We used uncomplicated Gram-negative bacteraemia as an illustrative case example because several published RCTs and observational studies have been conducted in similar patient populations. SOURCES: We searched MEDLINE for articles comparing treatment durations for gram-negative bacteremia from inception to June 9th, 2022. We included studies reporting on all-cause mortality and/or relapse at day 28-30. Data comparing short- versus long-course therapy were pooled by Bayesian random effects meta-analyses to assess the odds ratios (OR) of all-cause mortality and relapse at 30 days, stratified by study design. Parameters were summarized with median and 95% highest-density credible intervals (CrI). Posterior probabilities of OR > 1.0 were estimated. Observational studies were further examined to determine if and how they addressed potential sources of bias. CONTENT: We identified 1671 unique records and included 10 studies (seven observational and three RCTs). With respect to 30-day mortality, the Bayesian posterior probability that a longer course of therapy was better (i.e. OR >1.0) was 42% in RCTs (OR, 0.94; 95% CrI, 0.51-1.68) and 91% in observational studies (OR, 1.25; 95% CrI, 0.88-1.73). No observational study fully addressed all potential sources of bias. IMPLICATIONS: On the basis of our findings, we discuss future directions for antibiotic treatment duration trials, including approaches to limit sources of bias in observation data and novel trial designs.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. McDonald EG, Prosty C, Hanula R, et al. Observational versus randomized controlled trials to inform antibiotic treatment durations: a narrative review. Clin Microbiol Infect. 2022. PMID: 36108947. doi:10.1016/j.cmi.2022.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。